Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05JHB
|
|||
| Drug Name |
ArtemiC
|
|||
| Synonyms |
334007-19-1; Artemicapin C; CTK1B8490; DTXSID90469703; 6-hydroxy-7,8-methylenedioxy coumarin; DS-017116
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H6O5
|
|||
| Canonical SMILES |
C1OC2=C(C=C3C=CC(=O)OC3=C2O1)O
|
|||
| InChI |
1S/C10H6O5/c11-6-3-5-1-2-7(12)15-8(5)10-9(6)13-4-14-10/h1-3,11H,4H2
|
|||
| InChIKey |
BKFIQORTLXDLHQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 334007-19-1
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04382040) A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.